Atorvastatin is the preferred statin in patients with chronic kidney disease, per the PLANET trial.
(Note that the post below has a typo. The correct statement is that atorvastatin improved proteinuria, but had no effect on eGFR.)
#ckdHD #atorvastatinHD #rosuvastatinHD #kidneysHD #statinskidneysHD
✅✅ATORVASTATIN IS THE PREFERRED STATIN IN CKD PATIENTS
The most common cause of mortality in patients with CKD is cardiovascular, and therefore statins are recommended.
The PLANET (Prospective Evaluation of Proteinuria and Renal Function in Diabetic [and Nondiabetic] Patients With Progressive Renal Disease) trial showed that rosuvastatin was associated with decreased glomerular filtration rate (GFR) and increased proteinuria, whereas atorvastatin improved GFR and had no effect on proteinuria.